900
Participants
Start Date
June 29, 2018
Primary Completion Date
September 24, 2019
Study Completion Date
September 24, 2019
Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT
Dymista Nasal spray suspension
Azelastine Hydrochloride 0.137 MG/ACTUAT
AZEP Nasal spray solution
Fluticasone Propionate 0.05 MG/ACTUAT
Fluticasone propionate nasal spray suspension
Investigational Site 2, Beijing
Investigational Site 3, Beijing
Investigational Site 4, Beijing
Investigational Site 5, Beijing
Investigational Site, Chongqing
Investigational Site 1, Beijing
Investigational Site 1, Guangzhou
Investigational Site 2, Guangzhou
Investigational Site 1, Wuhan
Investigational Site 2, Wuhan
Investigational Site, Changsha
Investigational Site, Nanchang
Investigational Site, Changchun
Investigational Site, Tonghua
Investigational Site, Yanbian
Investigational Site, Jining
Investigational Site, Dalian
Investigational Site, Nanjing
Investigational Site 1, Qingdao
Investigational Site 2, Qingdao
Investigational Site, Yantai
Investigational Site, Zibo
Investigational Site, Shanghai
Investigational Site, Changzhi
Investigational Site, Taiyuan
Investigational Site 1, Xi’an
Investigational Site 2, Xi’an
Investigational Site, Chengdu
Investigational Site 1, Tianjin
Investigational Site 2, Tianjin
Investigational Site 3, Tianjin
Investigational Site 4, Tianjin
Investigational Site, Ürümqi
MEDA Pharma GmbH & Co. KG
INDUSTRY